Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teprotumumab - Horizon Pharma

Drug Profile

Teprotumumab - Horizon Pharma

Alternative Names: HZN 001; Insulin-like-growth-factor-1-receptor-antagonist-antibody-River-Vision-Development; R 1507; RG 1507; RO-4858696; RV 001-River-Vision

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab; Roche
  • Developer Horizon Pharma; Roche
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graves ophthalmopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graves ophthalmopathy
  • No development reported Diabetic macular oedema
  • Discontinued Advanced breast cancer; Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 29 Oct 2018 Updated efficacy and adverse events data from a phase II trial in Graves ophthalmopathy released by Horizon Pharma
  • 04 Oct 2018 Additional efficacy and safety data from a phase II trial in Graves ophthalmopathy released by Horizon Pharma
  • 04 Sep 2018 Horizon Pharma completes enrolment in the OPTIC-X phase III extension trial for Graves ophthalmopathy in USA, Italy and Germany (NCT03298867)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top